Skip Navigation

JNCI Journal of the National Cancer Institute 2004 96(23):1739; doi:10.1093/jnci/96.23.1739
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Zielinski, S. L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Zielinski, S. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 Oxford University Press

NEWS

In Brief

Sarah L. Zielinski

The first 10% of the full text of this article appears below.

Study Concludes Vioxx Should Have Been Withdrawn Years Ago

A meta-analysis of studies of rofecoxib (Vioxx) has found that there was evidence as early as 2000 that the drug increased the risk of myocardial infarction. Merck, the makers of Vioxx, recently announced the drug's withdrawal because of an increased risk of cardiovascular events among participants in . . . [Full Text of this Article]

Cancer Patients in Phase I Trials Less Likely to Die From Treatments Being Tested

No Need for Colposcopy in Screening of Young Women for Cervical Cancer, Study Suggests


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?